AJAllan Michael Jordan

Allan Michael Jordan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Allan Michael Jordan has a total of 466 co-authors. Here are the top co-authors by number of shared publications:

  • Donald Ogilvie

    Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK

    16 shared publications
  • Ian Waddell

    Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK

    13 shared publications
  • Donald J. Ogilvie

    Univ Manchester, Canc Res UK Manchester Inst, Drug Discovery Unit, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England

    11 shared publications
  • Ian D. Waddell

    Univ Manchester, Canc Res UK Manchester Inst, Drug Discovery Unit, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England

    11 shared publications
  • Nicola Hamilton

    University of Manchester Wilmslow Road

    10 shared publications
  • Bohdan Waszkowycz

    Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester , Wilmslow Road, Manchester, M20 4BX, United Kingdom

    9 shared publications

Latest Publications

  • Beyond Cytotoxic Payloads for Antibody Drug Conjugates─A Medicinal Chemistry Perspective

    by Allan Jordan, Stuart Best, Joshua Greally

    Despite significant research and investment, antibody–drug conjugates (ADCs) primarily rely on a limited number of broadly cytotoxic payloads that contribute significantly to toxicity. More recently, there has been a migration toward mechanistically targeted payloads, pairing improved antibodies with small molecules that act on disease-specific biology, improving precision and tolerability. Designing these next-generation payloads means rethinking some of our design metrics and guidelines derived from traditional medicinal chemistry: properties such as LogD, pKa, permeability, efflux, and metabolic stability must be carefully balanced to ensure efficient intracellular release while limiting systemic exposure. Here we discuss our observations around these properties and suggest design rules and guidelines for the optimization of next-generation ADC payloads.

  • Open Access

    Combining Artificial Intelligence and Human Expertise in Pursuit of Novel PolQ Inhibitors

    by Ageo Miccoli, Annabelle Charnock, Alexis Denis, Euan Fordyce, Cameron Franklin, Ennys Gheyouche, Ian Henderson, Christopher Housseman, Allan Jordan, Maxime Laugeois, et al.

    Application of generative AI, synergistically with traditional knowledge-based approaches, has expedited the discovery of small-molecule PolQ polymerase domain inhibitors. Leveraging AI-generated ligand designs, a structurally diverse set of compounds were synthesized and evaluated, ultimately identifying a novel oxime-based scaffold as a promising starting point. Although the initial hit demonstrated only modest biochemical potency, the oxime moiety─an unexplored vector in this chemical space─offered an opportunity for strategic substitution. Gratifyingly, using this strategy, a highly potent array of functionalized oxime PolQ inhibitors displaying promising initial ADME properties was delivered, underscoring the power of generative AI to unlock new chemical space and accelerate lead optimization.


  • To homeostasis and beyond! Recent advances in the medicinal chemistry of heterobifunctional derivatives

    by Diana Castagna, Benoit Gourdet, Roland Hjerpe, Philip MacFaul, Andrew Novak, Guillaume Revol, Etienne Rochette, Allan Jordan


  • Open Access

    Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders

    by Corentin Bouvier, Rachel Lawrence, Francesca Cavallo, Wendy Xolalpa, Allan Jordan, Roland Hjerpe, Manuel S. Rodriguez

    Proteolysis-targeting chimeras (PROTACs) describe compounds that bind to and induce degradation of a target by simultaneously binding to a ubiquitin ligase. More generally referred to as bifunctional degraders, PROTACs have led the way in the field of targeted protein degradation (TPD), with several compounds currently undergoing clinical testing. Alongside bifunctional degraders, single-moiety compounds, or molecular glue degraders (MGDs), are increasingly being considered as a viable approach for development of therapeutics, driven by advances in rational discovery approaches. This review focuses on drug discovery with respect to bifunctional and molecular glue degraders within the ubiquitin proteasome system, including analysis of mechanistic concepts and discovery approaches, with an overview of current clinical and pre-clinical degrader status in oncology, neurodegenerative and inflammatory disease.


  • Open Access

    Breaking Bad Proteins – Discovery Approaches and the Road to Clinic for Degraders

    by Corentin Bouvier, Rachel Lawrence, Francesca Cavallo, Wendy Xolalpa, Allan Jordan, Roland Hjerpe, Manuel S Rodriguez

    Proteolysis Targeting Chimeras (PROTACs) describe compounds that bind to and induce degradation of a target by simultaneously binding to a ubiquitin ligase. More generally referred to as bifunctional degraders, PROTACs have led the way in the field of targeted protein degradation (TPD) with several compounds currently undergoing clinical testing. Alongside bifunctional degraders, single-moiety compounds, or molecular glue degraders (MGDs), are increasingly being considered as a viable approach for development of therapeutics, driven by advances in rational discovery approaches. This review focusses on drug discovery with respect to bifunctional and molecular glue degraders within the ubiquitin proteasome system, including analysis of mechanistic concepts and discovery approaches, with an overview of current clinical and pre-clinical degrader status in oncology, neurodegenerative and inflammatory disease.


  • Synthesis in Medicinal Chemistry

    by Allan M. Jordan, Robert J. Young, Simon E Ward, Andrew Davis

    The discovery, optimisation and manufacture of medicines are processes underpinned by synthesis on scales from milligrams to tonnes; synthetic or semi-synthetic pharmaceuticals remain the cornerstones of modern medicines, as chemists innovate to deliver molecules to address contemporary challenges. This chapter reviews the crucial impact of synthesis, considering changing practices, contemporary developments in technology and methodology, and provides a view to how things may develop in future.

  • Top Cited Papers

    Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

    by Melissa B. Pappalardi, Kathryn Keenan, Mark Cockerill, Wendy A. Kellner, Alexandra Stowell, Christian Sherk, Kristen Wong, Sarath Pathuri, Jacques Briand, Michael Steidel, et al.


  • Open Access

    Molecularly profiled trials: toward a framework of actions for the “nil actionables”

    by Allan Michael Jordan

    The sequencing of tumour or blood samples is increasingly used to stratify patients into clinical trials of molecularly targeted agents, and this approach has frequently demonstrated clinical benefit for those who are deemed eligible. But what of those who have no clear and evident molecular driver? What of those deemed to have “nil actionable” mutations? How might we deliver better therapeutic opportunities for those left behind in the clamour toward stratified therapeutics? And what significant learnings lie hidden in the data we amass but do not interrogate and understand? This Perspective article suggests a holistic approach to the future treatment of such patients, and sets a framework through which significant additional patient benefit might be achieved. In order to deliver upon this framework, it encourages and invites the clinical community to engage more enthusiastically and share learnings with colleagues in the early drug discovery community, in order to deliver a step change in patient care.


  • Open Access

    Glucose 6-Phosphate Dehydrogenase from Trypanosomes: Selectivity for Steroids and Chemical Validation in Bloodstream Trypanosoma brucei

    by Cecilia Ortíz, Francesca Moraca, Marc Laverriere, Allan Jordan, Niall Hamilton, Marcelo A. Comini

    Glucose 6-phosphate dehydrogenase (G6PDH) fulfills an essential role in cell physiology by catalyzing the production of NADPH+ and of a precursor for the de novo synthesis of ribose 5-phosphate. In trypanosomatids, G6PDH is essential for in vitro proliferation, antioxidant defense and, thereby, drug resistance mechanisms. So far, 16α-brominated epiandrosterone represents the most potent hit targeting trypanosomal G6PDH. Here, we extended the investigations on this important drug target and its inhibition by using a small subset of androstane derivatives. In Trypanosoma cruzi, immunofluorescence revealed a cytoplasmic distribution of G6PDH and the absence of signal in major organelles. Cytochemical assays confirmed parasitic G6PDH as the molecular target of epiandrosterone. Structure-activity analysis for a set of new (dehydro)epiandrosterone derivatives revealed that bromination at position 16α of the cyclopentane moiety yielded more potent T. cruzi G6PDH inhibitors than the corresponding β-substituted analogues. For the 16α brominated compounds, the inclusion of an acetoxy group at position 3 either proved detrimental or enhanced the activity of the epiandrosterone or the dehydroepiandrosterone derivatives, respectively. Most derivatives presented single digit μM EC50 against infective T. brucei and the killing mechanism involved an early thiol-redox unbalance. This data suggests that infective African trypanosomes lack efficient NADPH+-synthesizing pathways, beyond the Pentose Phosphate, to maintain thiol-redox homeostasis.


  • Open Access

    Discovery and Optimization of wt-RET/KDR-Selective Inhibitors of RETV804M Kinase

    by Rebecca Newton, Bohdan Waszkowycz, Chitra Seewooruthun, Daniel Burschowsky, Mark Richards, Samantha Hitchin, Habiba Begum, Amanda Watson, Eleanor French, Niall Hamilton, et al.

    A combination of focused library and virtual screening, hit expansion, and rational design has resulted in the development of a series of inhibitors of RETV804M kinase, the anticipated drug-resistant mutant of RET kinase. These agents do not inhibit the wild type (wt) isoforms of RET or KDR and therefore offer a potential adjunct to RET inhibitors currently undergoing clinical evaluation.